![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » PHASE I/II ANTI-CANCER DRUG TRIAL CONDUCTED
PHASE I/II ANTI-CANCER DRUG TRIAL CONDUCTED
July 20, 2005
Nicholas Piramal India announced the commencement of Phase I/II clinical studies for the anti-cancer drug molecule P276-00. It could take nine to 12 months to enroll 30-35 patients to complete the Phase I/II study, which will help determine a safe and possible efficacious dose to be used in further clinical studies.
The improvements may be observed on CT scans of the treated patients, an innovative clinical trial design is being employed which will also help evaluate the drug's effect even at the cellular level. This will assist in further refining the strategies for additional Phase II studies in treating cancer.
P276-00 is an inhibitor of a key protein that is required for cell division. Malignant (cancerous) cells have an unchecked growth pattern. Because P276-00 blocks a key enzyme at the 'entry stage' it prevents the cells from synthesizing other ingredients that are required before they divide, which forces the cells to embark on the path of programmed cell death.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct